REGENXBIO Inc.
Close on Oct 19, 2026
- Market cap
- $379.06M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $108.00M | $0.43 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $6.40M | $-1.72 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | $30.30M | $-1.30 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $29.70M | $-1.20 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $21.40M | $-1.38 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $89.00M | $0.12 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | After market close | $21.20M | $-1.01 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $24.20M | $-1.17 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | After market close | – | – | – |
Press releases
Announcements Regenxbio filed with the SEC
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
Other events · EX-99.1 to Form 8-K
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE ® Study of RGX-202
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
Other events · EX-99.1 to Form 8-K
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
Other events · EX-99.1 to Form 8-K
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
OF AFFINITY DUCHENNE ® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
Other events · EX-99.1 to Form 8-K
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K
ROCKVILLE, Md. June 12, 2024 REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran Simpson, Chief Operating
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
Other events · EX-99.1 to Form 8-K
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
Results of operations · EX-99 to Form 8-K
REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights
Results of operations · EX-99 to Form 8-K
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights
Results of operations · EX-99.1 to Form 8-K
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18 th Annual WORLD Symposium TM
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
REGENXBIO Presents Positive Initial Data from Phase I/II Trial of
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
REGENXBIO Announces Closing of Eye Care Collaboration Agreement with
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K